• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

多发性骨髓瘤患者体内 CD4+FOXP3+调节性 T 细胞和 CD14+HLA-DR⁻/low 髓系来源抑制细胞水平升高,树突状细胞水平降低。

Increased level of both CD4+FOXP3+ regulatory T cells and CD14+HLA-DR⁻/low myeloid-derived suppressor cells and decreased level of dendritic cells in patients with multiple myeloma.

机构信息

Center for Cancer Immune Therapy, Department of Haematology, Herlev Hospital, University of Copenhagen, Herlev, Denmark.

出版信息

Scand J Immunol. 2010 Dec;72(6):540-7. doi: 10.1111/j.1365-3083.2010.02463.x.

DOI:10.1111/j.1365-3083.2010.02463.x
PMID:21044128
Abstract

Patients with multiple myeloma (MM) suffer from a general impaired immunity comprising deficiencies in humoral responses, T-cell responses as well as dendritic cell (DC) function. Thus, to achieve control of tumour growth through immune therapy constitutes a challenge. Careful evaluation of the immune status in patients with MM seems crucial prior to active immune therapy. We evaluated the proportion of both, DC, Treg cells and myeloid-derived suppressor cells (MDSC) in peripheral blood from patients with MM at diagnosis and in remission as well as patients with monoclonal gammopathy of undetermined significance (MGUS). We found that the proportion of both myeloid (m) DC and plasmacytoid (p) DC in patients at diagnosis was lowered compared to control donors, while only the proportion of pDC in patients in remission and with MGUS was significantly lower than in controls. The proportion of CD4+FOXP3+ Treg cells was increased in patients at diagnosis and not in patients in remission or with MGUS. Also, Treg cells from patients with MM were functionally intact as they were able to inhibit proliferation of both CD4 and CD8 T cells. Finally, we observed an increase in the proportion of CD14+HLA-DR⁻/low MDSC in patients with MM at diagnosis, illustrating that this cell fraction is also distorted in patients with MM. Taken together, our results illustrate that, both mDC, pDC, Treg cells and MDSC are affected in patients with MM underlining the fact that the immune system is dysregulated as a consequence of the disease.

摘要

多发性骨髓瘤(MM)患者存在普遍的免疫功能受损,包括体液免疫应答、T 细胞应答以及树突状细胞(DC)功能缺陷。因此,通过免疫疗法控制肿瘤生长是一个挑战。在进行主动免疫治疗之前,仔细评估 MM 患者的免疫状态似乎至关重要。我们评估了诊断时和缓解期 MM 患者以及单克隆丙种球蛋白病不确定意义(MGUS)患者外周血中 DC、Treg 细胞和髓系来源抑制细胞(MDSC)的比例。我们发现,与对照供体相比,诊断时 MM 患者的髓样(m)DC 和浆细胞样(p)DC 的比例降低,而仅缓解期和 MGUS 患者的 pDC 比例明显低于对照。诊断时 CD4+FOXP3+Treg 细胞的比例增加,而缓解期或 MGUS 患者的比例没有增加。此外,MM 患者的 Treg 细胞功能完整,因为它们能够抑制 CD4 和 CD8 T 细胞的增殖。最后,我们观察到诊断时 MM 患者中 CD14+HLA-DR⁻/low MDSC 的比例增加,表明该细胞亚群在 MM 患者中也存在扭曲。总之,我们的结果表明,mDC、pDC、Treg 细胞和 MDSC 在 MM 患者中均受到影响,这突出了免疫系统因疾病而失调的事实。

相似文献

1
Increased level of both CD4+FOXP3+ regulatory T cells and CD14+HLA-DR⁻/low myeloid-derived suppressor cells and decreased level of dendritic cells in patients with multiple myeloma.多发性骨髓瘤患者体内 CD4+FOXP3+调节性 T 细胞和 CD14+HLA-DR⁻/low 髓系来源抑制细胞水平升高,树突状细胞水平降低。
Scand J Immunol. 2010 Dec;72(6):540-7. doi: 10.1111/j.1365-3083.2010.02463.x.
2
CD4(+)CD25(+)FoxP3(+) regulatory T cells are increased whilst CD3(+)CD4(-)CD8(-)alphabetaTCR(+) Double Negative T cells are decreased in the peripheral blood of patients with multiple myeloma which correlates with disease burden.在多发性骨髓瘤患者的外周血中,CD4(+)CD25(+)FoxP3(+)调节性T细胞增加,而CD3(+)CD4(-)CD8(-)αβTCR(+)双阴性T细胞减少,这与疾病负担相关。
Br J Haematol. 2009 Mar;144(5):686-95. doi: 10.1111/j.1365-2141.2008.07530.x. Epub 2008 Dec 26.
3
CD4+CD25+FOXP3+ T regulatory cells reconstitute and accumulate in the bone marrow of patients with multiple myeloma following allogeneic stem cell transplantation.在异基因干细胞移植后,CD4+CD25+FOXP3+调节性T细胞在多发性骨髓瘤患者的骨髓中重建并积聚。
Haematologica. 2008 Mar;93(3):423-30. doi: 10.3324/haematol.11897. Epub 2008 Feb 20.
4
Immunoregulatory T cells in the peripheral blood of melanoma patients treated with melanoma antigen-pulsed mature monocyte-derived dendritic cell vaccination.接受黑色素瘤抗原脉冲成熟单核细胞来源树突状细胞疫苗治疗的黑色素瘤患者外周血中的免疫调节性T细胞
J Dermatol Sci. 2009 Apr;54(1):31-7. doi: 10.1016/j.jdermsci.2008.11.007. Epub 2009 Jan 20.
5
Circulating dendritic cells subsets and CD4+Foxp3+ regulatory T cells in adult patients with chronic ITP before and after treatment with high-dose dexamethasome.大剂量地塞米松治疗前后成年慢性免疫性血小板减少症患者循环树突状细胞亚群和CD4+Foxp3+调节性T细胞的情况
Eur J Haematol. 2007 Oct;79(4):310-6. doi: 10.1111/j.1600-0609.2007.00917.x. Epub 2007 Aug 10.
6
Increase of circulating CD4+CD25highFoxp3+ regulatory T cells in patients with metastatic renal cell carcinoma during treatment with dendritic cell vaccination and low-dose interleukin-2.在树突状细胞疫苗接种和低剂量白细胞介素-2治疗转移性肾细胞癌患者期间,循环 CD4+CD25highFoxp3+调节性 T 细胞增加。
J Immunother. 2010 May;33(4):425-34. doi: 10.1097/CJI.0b013e3181cd870f.
7
Generation of immune inhibitory dendritic cells and CD4+T regulatory cells inducing by TGF-beta.由转化生长因子-β诱导产生免疫抑制性树突状细胞和CD4+T调节细胞。
Iran J Allergy Asthma Immunol. 2009 Mar;8(1):25-30.
8
Proportions of circulating T cells with a regulatory cell phenotype increase with HIV-associated immune activation and remain high on antiretroviral therapy.具有调节性细胞表型的循环T细胞比例随HIV相关免疫激活而增加,并在抗逆转录病毒治疗期间保持高位。
AIDS. 2007 Jul 31;21(12):1525-34. doi: 10.1097/QAD.0b013e32825eab8b.
9
Novel role of plasmacytoid dendritic cells in humans: induction of interleukin-10-producing Treg cells by plasmacytoid dendritic cells in patients with rheumatoid arthritis responding to therapy.浆细胞样树突状细胞在人类中的新作用:类风湿关节炎患者对治疗有反应时,浆细胞样树突状细胞诱导产生白细胞介素-10的调节性T细胞。
Arthritis Rheum. 2010 Jan;62(1):53-63. doi: 10.1002/art.25037.
10
Human tumor-released microvesicles promote the differentiation of myeloid cells with transforming growth factor-beta-mediated suppressive activity on T lymphocytes.人类肿瘤释放的微泡通过转化生长因子-β介导的对T淋巴细胞的抑制活性促进髓样细胞的分化。
Cancer Res. 2006 Sep 15;66(18):9290-8. doi: 10.1158/0008-5472.CAN-06-1819.

引用本文的文献

1
Molecular mechanisms and clinical value of the correlation between depression and cancer.抑郁症与癌症相关性的分子机制及临床价值
Med Oncol. 2025 May 17;42(6):214. doi: 10.1007/s12032-025-02763-9.
2
Expanded tumor-associated polymorphonuclear myeloid-derived suppressor cells in Waldenstrom macroglobulinemia display immune suppressive activity.华氏巨球蛋白血症中扩增的肿瘤相关多形核骨髓来源的抑制性细胞表现出免疫抑制活性。
Blood Cancer J. 2024 Dec 18;14(1):217. doi: 10.1038/s41408-024-01173-w.
3
Exosome therapeutics for non-small cell lung cancer tumorigenesis.
用于非小细胞肺癌肿瘤发生的外泌体疗法
Cancer Cell Int. 2024 Oct 30;24(1):360. doi: 10.1186/s12935-024-03544-6.
4
Galectin-9 - ligand axis: an emerging therapeutic target for multiple myeloma.半乳糖凝集素-9 - 配体轴:多发性骨髓瘤的新兴治疗靶点。
Front Immunol. 2024 Sep 25;15:1469794. doi: 10.3389/fimmu.2024.1469794. eCollection 2024.
5
Role of Immune Cells and Immunotherapy in Multiple Myeloma.免疫细胞与免疫疗法在多发性骨髓瘤中的作用
Life (Basel). 2024 Apr 1;14(4):461. doi: 10.3390/life14040461.
6
Multiple influence of immune cells in the bone metastatic cancer microenvironment on tumors.骨转移癌微环境中免疫细胞对肿瘤的多重影响。
Front Immunol. 2024 Feb 23;15:1335366. doi: 10.3389/fimmu.2024.1335366. eCollection 2024.
7
Decreased circulating myeloid-derived suppressor cell count at the engraftment is one of the risk factors for multiple myeloma relapse after autologous hematopoietic stem cell transplantation.移植时循环髓系来源抑制细胞计数降低是自体造血干细胞移植后多发性骨髓瘤复发的危险因素之一。
Heliyon. 2024 Feb 16;10(5):e26362. doi: 10.1016/j.heliyon.2024.e26362. eCollection 2024 Mar 15.
8
What happens to regulatory T cells in multiple myeloma.多发性骨髓瘤中调节性T细胞会发生什么变化。
Cell Death Discov. 2023 Dec 21;9(1):468. doi: 10.1038/s41420-023-01765-8.
9
Identification of a novel cuproptosis-related gene signature for multiple myeloma diagnosis.鉴定多发性骨髓瘤诊断的新型铜死亡相关基因特征。
Immun Inflamm Dis. 2023 Nov;11(11):e1058. doi: 10.1002/iid3.1058.
10
Perspectives on the Treatment of Multiple Myeloma.多发性骨髓瘤的治疗观点。
Oncologist. 2024 Mar 4;29(3):200-212. doi: 10.1093/oncolo/oyad306.